S&P Global Reiterates “€83.00” Price Target for Sanofi SA (SAN)
Sanofi SA (EPA:SAN) has been assigned a €83.00 ($97.65) target price by stock analysts at S&P Global in a report released on Friday. The firm presently has a “neutral” rating on the stock.
Several other equities research analysts have also recently commented on the stock. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi SA in a research report on Thursday, July 20th. Kepler Capital Markets set a €89.00 ($104.71) price objective on shares of Sanofi SA and gave the company a “buy” rating in a research report on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research report on Wednesday, July 26th. BNP Paribas set a €83.00 ($97.65) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research report on Wednesday, September 6th. Finally, Morgan Stanley set a €92.00 ($108.24) price objective on shares of Sanofi SA and gave the company a “buy” rating in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of €87.24 ($102.63).
ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/s83-00-price-target-for-sanofi-sa-san.html.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.